Myomo (MYO) Peer Comparison

$1.42

$0.38 (36.06%)

As on 02-Sep-2026 14:42EDT

Market cap

$69 Mln

Revenue (TTM)

$43 Mln

P/E Ratio

--

P/B Ratio

12.6

Div. Yield

0 %

Edit

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	69	12,753	10,906	9,948	9,762
Revenue ($ Mln)	43	1,505	613	785	2,589
Net Profit ($ Mln)	-14.51	160.59	-188.05	41.54	222.40
Net Margin (%)	-33.53	10.67	-30.68	5.29	8.59
RoE (%)	-168.37	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	12.64	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	43.26	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	13.69	483.98	127.96	384.30	1,245.50
Gross Profit	26.89	942.44	393.22	347.62	1,343.60
Operating Expenses	41.27	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-11.70	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-14.07	203.83	-192.83	52.15	350.40
Provision for Tax	0.44	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-14.51	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	-7.48	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	5.83	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	18.90	210.18	135.71	705.49	2,116.80
Current Liabilities	10.61	233.78	102.33	132.66	961.30
Total Liabilities	38.64	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	10.82	630.60	404.74	1,749.63	7,231.50
Current Assets	24.53	1,344.12	515.78	1,200.55	3,020.50
Total Assets	38.64	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	20.08	212.71	102.84	690.94	1,203.70
Net Current Assets	13.92	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-14.51	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-7.06	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	11.43	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-48.97	11.76	-22.53	1.79	8.98
ROE (%)	-168.37	10.86	-28.10	1.97	3.04
ROA (%)	-30.11	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-15.04	13.63	-30.58	9.87	-5.99
Net Margin (%)	-33.53	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	6.14	17.55	41.55	16.49	1.37
EBIT Growth (%)	26.62	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-55.60	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-51.18	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-67.77	17.33	-12.65	2.16	2.19

Valuation Ratios

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-2.45	68.93	-34.59	189.42	--
Price / Book Value	3.34	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.16	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	1.98	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.20	0.01	0.00	0.01	0.06
Current Ratio	2.31	5.75	5.04	9.05	3.14
Quick Ratio	2.01	3.86	4.46	7.64	2.33
Interest Coverage	-6.86	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Myomo (MYO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	11.43	12.65	22.67	20.09	17.06
Asset Turnover	0.90	0.74	0.59	0.26	0.24
Receivable days	35.35	46.54	60.95	72.41	65.39
Inventory Days	81.81	331.92	193.84	146.53	221.09
Payable days	34.83	26.16	60.19	29.05	37.02
Cash Conversion Cycle	82.32	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly